

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UMD, Inc.	03/09/2010
RECEIVING PARTY DATA	
Name:	Femina Pharma Incorporated
Street Address:	3407 E. Coast Avenue
Internal Address:	h502
City:	Miami
State/Country:	FLORIDA
Postal Code:	33137
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10444634
CORRESPONDENCE DATA	
Fax Number:	(703)312-6666
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(703) 312-6600
Email:	aschiavelli@antonelli.com
Correspondent Name:	Alan E. Schiavelli
Address Line 1:	1300 N. 17th Street
Address Line 2:	Sutie 1800
Address Line 4:	Arlington, VIRGINIA 22209
ATTORNEY DOCKET NUMBER:	1574.50849X00
NAME OF SUBMITTER:	Alan E. Schiavelli, Reg. No. 32,087

Total Attachments: 8
 source=Recordation#page1.tif
 source=Assignment#page1.tif

501403046

PATENT
REEL: 025621 FRAME: 0034

OP \$40.00 10444634

source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif

Form PTO-1595
(Rev. 10/02)
OMB No. 0651-0027 (exp. 6/30/2005)

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

Attorney Docket No. 1574.50849X00

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): UMD, Inc. Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies) Name: Femina Pharma Incorporated Street Address: 3407 E. Coast Avenue, h502 City: State: Zip: Miami, FL 33137 Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance/ Execution Date: March 9, 2010. <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other .	

4. Application number(s) or patent number(s): A. Patent Application No.(s) 10/444,634	<input type="checkbox"/> This document is being filed together with a new application. B. Patent Registration No.(s) Additional number(s) attached <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
--	--

5. Name and address of party to whom correspondence concerning document should be mailed: Name: ANTONELLI, TERRY, STOUT & KRAUS, LLP Internal Address: 1300 NORTH 17TH STREET – SUITE 1800 City: ARLINGTON State: VA Zip 22209 Phone Number: (703) 312-6600 Facsimile Number: (703) 312-6666 Email Address: email@antonelli.com	6. Total number of applications and patents involved <input checked="" type="checkbox"/> 7. Total fee (37 CFR 3.41)..... \$40.00 <input checked="" type="checkbox"/> Authorized to be charged by credit card <input type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title) 8. Payment Information: a. Credit Card Last 4 numbers: 1065 Expiration date: 06/2014 b. Deposit account number: 01-2135 Authorized User Name: Alan E. Schiavelli
--	--

DO NOT USE THIS SPACE

9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>		
Alan E. Schiavelli, Reg#32,087 _____ Name of Person Signing	/Alan E. Schiavelli/ _____ Signature	01/11/2010 _____ Date

Total number of pages including cover sheet, attachments, and document:

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

ASSIGNMENT

WHEREAS, **UMD, Inc.**, of Cincinnati, Ohio, a Delaware corporation, hereinafter referred to as "ASSIGNOR"), is the owner of the Patents and Patent Applications listed on Appendix A hereto; and

WHEREAS, **Femina Pharma Incorporated**, of Surfside, Florida, a Delaware corporation (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire interest in said Patents and Patent applications.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, said ASSIGNOR, hereby sells, assigns, and transfers and sets over, unto said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in, to and under said Patents and Patent Applications, and all divisions, renewals, and continuations thereof, and all Patents of the United States and any country or countries foreign to the United States, which may be granted on said Patent Applications, and all reissues, reexaminations and extensions of said Patents and Patent Applications; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed in the United States or any country or countries foreign to the United States and claiming priority rights to said Patents or Patent Applications.

ASSIGNOR hereby authorizes and requests the Director of the United States Patent and Trademark Office, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

ASSIGNOR hereby covenants and agrees that it has full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

ASSIGNOR hereby further covenants and agrees that it will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any fact known to it respecting said

invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue, reexamination and foreign applications, make all rightful oaths, and generally do everything possible to aid said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said Patents and Patent Applications in all countries.

UMD, Inc.

By: Richard J. Daugustine


Title: President + CEO

State of Ohio :

County of Hawthorn :

ss

On March 9th, 2010, before me, the undersigned Notary Public, personally appeared Richard J. Daugustine, known to me to be the person who name is subscribed to above, and who has acknowledged that (s)he executed the same for the purposes expressed therein.



ROB L. SEIPELT
Notary Public, State of Ohio
My Commission Expires
March 1, 2011

Rob L. Seipelt
Notary Public

My Commission Expires: March 1, 2011

APPENDIX A

GRANTED/PENDING US CASES

UMD DOCKET NO.	CASE TITLE	CASE STATUS	COUNTRY	PATENT/SERIAL NO.
3715.02	Device and Method for Treatment of Dysmenorrhea	Registered/Granted	US	6,197,327
3715.02-1	Device and Method for Treatment of Dysmenorrhea	Registered/Granted	US	6,086,909
3715.02-2	Device and Method for Treatment of Vaginal Fungal Infection	Registered/Granted	US	6,416,779
3715.07-1	Vaginal Delivery of Bisphosphonates for Prevention of Osteoporosis	Registered/Granted	US	6,572,874
3715.07-2	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Registered/Granted	US	6,905,701
3715.08-1	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Registered/Granted	US	6,982,091
3715.08-2	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Pending/Published	US	11/208,209
3715.08-4	A Method For Augmentation of Intraepithelial and Systemic Exposure of Therapeutic	Pending/Published	US	11/522,126
3715.12-1	Intravaginal Mucosal or Transmucosal Delivery of Antimigraine	Pending/Published	US	10/600,849
3715.13-2	Coated Vaginal Device Comprising a Pharmaceutical Composition	Pending/Published	US	11/126,863
3715.17-1	Therapeutic Compositions for Drug Delivery to and Through Muc	Pending/Published	US	10/698,794
3715.24-1	Coated Vaginal Device Comprising a Pharmaceutical Composition	Pending/Published	US	11/180,076
4005400-173664	pH Modulated Films for Delivery of Actives	Pending	US	12/130,279

FOREIGN CASES

UMD DOCKET NO.	CASE TITLE	CASE STATUS	COUNTRY	APPLICATION/REGISTRATION NO.
3715.02-2AU	Device and Method for Treatment of Vaginal Fungal Infection	Registered/Granted	AU	2001281287
3715.02-2BR	Device and Method for Treatment of Vaginal Fungal Infection	Closed	BR	P10112571-0
3715.02-2CA	Device and Method for Treatment of Vaginal Fungal Infection	Closed	CA	2,416,050
3715.02-2CN	Device and Method for Treatment of Vaginal Fungal Infection	Registered/Granted	CN	01812514.X
3715.02-2EP	Device and Method for Treatment of Vaginal Fungal Infection	Closed	EP	01939766.5
3715.02-2HK	Device and Method for Treatment of Vaginal Fungal Infection	Published	HK	03106688.1
3715.02-2IL	Device and Method for Treatment of Vaginal Fungal Infection	Closed	IL	153719
3715.02-JP	Device and Method for Treatment of Vaginal Fungal Infection	Closed	JP	2002-508356

3715.02-2MX	Device and Method for Treatment of Vaginal Fungal Infection	Closed		MX	012819
3715.02-2NZ	Device and Method for Treatment of Vaginal Fungal Infection	Registered/Granted		NZ	524047
3715.02-2PCT	Device and Method for Treatment of Vaginal Fungal Infection	Closed		PC	PCT/US01/41128
3715.02AU	Device and Method for Treatment of Dysmenorrhea	Closed		AU	735407
3715.02AUDI	Device and Method for Treatment of Dysmenorrhea	Closed		AU	54192/01
3715.02BR	Device and Method for Treatment of Dysmenorrhea	Closed		BR	9810089-0
3715.02CA	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		CA	2,293,346
3715.02CN	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		CN	98807142.8
3715.02D1MX	Device and Method for Treatment of Dysmenorrhea	Closed		MX	PA/a/2001/010560
3715.02D1NZ	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		NZ	60/049,325
3715.02EP	Device and Method for Treatment of Dysmenorrhea	Closed		EP	98924918.0
3715.02HK	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		HK	PCT/US98/10785
3715.02IL	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		IL	133431
371.02JP	Device and Method for Treatment of Dysmenorrhea	Closed		JP	11-502556
3715.02MX	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		MX	9911480
3715.02NZ	Device and Method for Treatment of Dysmenorrhea	Registered/Granted		NZ	502120
3715.02PCT	Device and Method for Treatment of Dysmenorrhea	Closed		PC	PCT/US98/10785
3715.07-1AU	Vaginal Delivery of Bisphosphonates	Registered/Granted		AU	2001278920
3715.07-1BR	Vaginal Delivery of Bisphosphonates	Closed		BR	PI0113134-6
3715.07-1CA	Vaginal Delivery of Bisphosphonates	Closed		CA	2,416,122
3715.07-1CN	Vaginal Delivery of Bisphosphonates	Registered/Granted		CN	01815921.4
3715.07-1EP	Vaginal Delivery of Bisphosphonates	Closed		EP	01957150.4
3715.07-1HK	Vaginal Delivery of Bisphosphonates	Closed		HK	031016689.0
3715.07-1HU	Vaginal Delivery of Bisphosphonates	Published		HU	P0303189
3715.07-1IL	Vaginal Delivery of Bisphosphonates	Closed		IL	154134
3715.07-1JP	Vaginal Delivery of Bisphosphonates	Published		JP	2002-515186
3715.07-1MX	Vaginal Delivery of Bisphosphonates	Closed		MX	000803
3715.07-1NO	Vaginal Delivery of Bisphosphonate	Closed		NO	2003/0422
3715.07-1NZ	Vaginal Delivery of Bisphosphonates	Registered/Granted		NZ	524069

3715.07-1PCT	Vaginal Delivery of Bisphosphonates	Closed	PC	PCT/US01/22205
3715.07-1PO	Vaginal Delivery of Bisphosphonates	Closed	PL	P365884
3715.07-1TW	Vaginal Delivery of Bisphosphonates	Closed	TW	90118296
3715.07-2AU	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	AU	2004207456
3715.07-2BR	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	BR	PI 0406635-9
3715.07-2CA	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	CA	2,514,109
3715.07-2CN	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Published	CN	200480002695.1
3715.07-2EP	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Published	EP	04702183.7
3715.07-2IL	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	IL	169694
3715.07-2JP	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Published	JP	502,821/2006
3715.07-2MX	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	MX	2005/007791
3715.07-2NO	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	NO	20053657
3715.07-2NZ	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Registered/Granted	NZ	541776
3715.07-2PCT	Improved Formulations For Transmucosal Vaginal Delivery of Bi	Closed	PC	PCT/US04/00902
3715.08-1AU	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Registered/Granted	AU	2002329842
3715.08-1CA	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Closed	CA	2,457,526
3715.08-1EP	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Closed	EP	02766096.8
3715.08-1JP	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Published	JP	524,524/2003
3715.08-4AU	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Unfiled	AU	2006292507
3715.08-4CA	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Closed	CA	2,622,746
3715.08-4EP	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Published	EP	06824976.2
3715.08-4IL	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Closed	IL	190194
3715.08-4JP	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Closed	JP	531,372/2008
3715.08-4PCT	A Method for Augmentation of Intraepithelial and Systemic Exposure of	Closed	PC	PCT/US06/36087
3715.08.1PCT	Vaginal Delivery of Chemotherapeutic Agents and Inhibitors of	Closed	PC	PCT/US02/27027
3715.10-1AU	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	AU	233,653
3715.10-1BR	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	BR	PI 0311530-5
3715.10-1CA	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	CA	2,486,909

3715.10-1CN	Compositions and Method for Transmucosal Drug Delivery and Cr	Published	CN	03814727.0
3715.10-1EP	Compositions and Method for Transmucosal Drug Delivery and Cr	Published	EP	03729092.1
3715.10-1HK	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	HK	06102039.3
3715.10-1JP	Compositions and Method for Transmucosal Drug Delivery and Cr	Published	JP	506,788/2004
3715.10-1MX	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	MX	011584
3715.10-1NO	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	NO	20045140
3715.10-1PCT	Compositions and Method for Transmucosal Drug Delivery and Cr	Closed	PC	PCT/US03/16313
3715.12-2AU	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Registered/Granted	AU	2005271865
3715.12-2CA	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Closed	CA	2,573,583
3715.12-2EP	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Published	EP	05770740.8
3715.12-2IL	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Pending	IL	180243
3715.12-2JP	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Closed	JP	521,543/2007
3715.12-2PCT	Coated Vaginal Device For Delivery of Anti-Migraine and Anti-	Closed	PC	PCT/US05/24581
3715.17-1AU	Therapeutic Compositions for Drug Delivery to and Through Cov	Closed	AU	2003286796
3715.17-1BR	Therapeutic Compositions for Drug Delivery to and Through Cov	Closed	BR	PI 0315194-8
3715.17-1CA	Therapeutic Compositions for Drug Delivery to and Through Muc	Closed	CA	2,504,283
3715.17-1CN	Therapeutic Compositions for Drug Delivery to and Through Cov	Published	CN	200380104617.8
3715.17-1EP	Therapeutic Compositions for Drug Delivery to and Through Muc	Published	EP	03778010.3
3715.17-1HK	Therapeutic Compositions for Drug Delivery to and Through Cov	Published	HK	06101449.9
3715.17-1IL	Therapeutic Compositions for Drug Delivery to and Through Muc	Closed	IL	168178
3715.17-1JP	Therapeutic Compositions for Drug Delivery to and Through Muc	Published	JP	502,233/2005
3715.17-1MX	Therapeutic Compositions for Drug Delivery to and Through Muc	Closed	MX	2005/004578
3715.17-1NO	Therapeutic Compositions for Drug Delivery to and Through Cov	Closed	NO	2005 1964
3715.17-1NZ	Therapeutic Compositions for Drug Delivery to and Through Cov	Published	Ni	540318
3715.17-1PCT	Therapeutic Compositions for Drug Delivery to and Through Cov	Closed	PC	PCT/US03/34643
3715.24	Coated Vaginal Device Comprising a Pharmaceutical Composition	Closed	US	60/587,454
3715.24-1	Coated Vaginal Device Comprising a Pharmaceutical Composition	Published	US	11/180,076
3715.24-1AU	Coated Vaginal Device Comprising a Pharmaceutical Composition	Closed	AU	2005271786

3715.24-1CA	Coated Vaginal Device Comprising a Pharmaceutical Composition	Closed	CA	2,578,247
3715.24-1EP	Coated Vaginal Device Comprising a Pharmaceutical Composition	Published	EP	05791044.0
3715.24-1JP	Coated Vaginal Device Comprising a Pharmaceutical Composition	Closed	JP	521,616/2007
3715.24-1PCT	Coated Vaginal Device Comprising a Pharmaceutical Composition	Closed	PC	PCT/US05/24872